CoChat

Liraglutide

Drucker, Daniel J., Dritselis, Argyris, Kirkpatrick, Peter · 2010 · Nature Reviews Drug Discovery

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

In January 2010, liraglutide (Victoza; Novo Nordisk)--an injectable glucagon-like peptide 1 receptor agonist--was approved by the US FDA to improve glycaemic control in adults with type 2 diabetes mellitus.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrd3148

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 2

  1. Knudsen, L. B. et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 4 Mar 2010 (doi: 10.1210/en.2009–1272) · DOI · Paper page
  2. Vosser, R. Hauber, A. & Gordon, J. D. Europe Equity Research Report (J. P. Morgan, 5 Feb 2010).

Cited by

See all 183

Metadata

Authors
Drucker, D. J., Dritselis, A., & Kirkpatrick, P.
Affiliations
Mount Sinai Hospital (CA)
Venue
Nature Reviews Drug Discovery
Published
2010-04
Volume
9
Issue
4
Pages
267-268
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W4245650535
Cited by
181
References
13
Citations by year
2026: 11 · 2025: 19 · 2024: 13 · 2023: 12 · 2022: 21 · 2021: 9 · 2020: 10 · 2019: 11 · 2018: 8 · 2017: 8 · 2016: 6 · 2015: 8 · 2014: 11 · 2013: 12 · 2012: 6
FWCI
8.22
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
liraglutide, GLP-1 receptor agonists, type 2 diabetes, glycemic control, FDA approval, injectable drugs
MeSH terms
Liraglutide, Adult, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, United States, United States Food and Drug Administration, Randomized Controlled Trials as Topic, Drug Approval, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.